AACR 2019 PARP inhibitors can shrink tumours in pancreatic cancer patients with specific mutations

AACR 2019: PARP inhibitors can shrink tumours in pancreatic cancer patients with specific mutations

10:08 EDT 3 Apr 2019 | ecancermedicalscience

Switching pancreatic cancer patients to the PARP inhibitor rucaparib as maintenance therapy instead of continuing intensive chemotherapy either shrunk tumours or stopped them from growing in 17 of 19 patients in an interim analysis from a trial at the...

More From BioPortfolio on "AACR 2019: PARP inhibitors can shrink tumours in pancreatic cancer patients with specific mutations"